<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044862</url>
  </required_header>
  <id_info>
    <org_study_id>RMN-AMIGOS</org_study_id>
    <secondary_id>3U10HD055925-02S1</secondary_id>
    <secondary_id>5U10HD055925</secondary_id>
    <secondary_id>3U10HD039005-08S1</secondary_id>
    <secondary_id>5U10HD039005</secondary_id>
    <nct_id>NCT01044862</nct_id>
  </id_info>
  <brief_title>Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation</brief_title>
  <acronym>AMIGOS</acronym>
  <official_title>Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this application is to identify a pharmacologic agent which helps couples in
      whom the female partner ovulates regularly successfully obtain their goal of delivering a
      healthy child, whose use will result in low rates of multiple gestations. The central
      hypothesis is that, in infertile ovulatory women undergoing ovarian stimulation (OS) and
      intrauterine insemination (IUI), the use of aromatase inhibitors (AI) will stimulate the
      ovaries sufficiently to produce no reduction in the rate of pregnancy, while significantly
      reducing the numbers of multiple gestational pregnancies that result from stimulation with
      clomiphene citrate (CC) or follicle stimulating hormone (FSH). The rationale for the proposed
      research is that reduction of multiple pregnancy rates could significantly reduce maternal
      and neonatal morbidity and mortality, as well as the cost of healthcare for these individuals
      and society.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient Population

      The population will consist of 900 women up to and including women ≥18 to ≤40 years years of
      age (at time of randomization) desirous of conceiving who will be recruited over
      approximately a two year period from the Reproductive Medicine Network (RMN) clinical sites
      and possibly from the Specialized Cooperative Center Programs in Reproductive Research
      (SCCPIR) sites, through public notification programs.

      Study Design

      This will be a multi-center, prospective, partially blinded clinical trial of gonadotropins
      vs. clomiphene citrate vs. aromatase inhibitors. The randomization scheme will be coordinated
      through the data coordination center (DCC) and the randomization will be stratified by each
      participating site and within each site for ages 18-34 and 35-40.

      Treatment

      Patients will be randomized to receive either FSH, CC, or an AI according to randomization
      tables generated by a computer randomization program. Treatment assignments will be blocked
      by site and age group. Subjects randomized to pill treatment will receive medication in
      double blinded fashion, receiving one type of pill (overcoated CC or AI). Subjects randomized
      to injectable medication(FSH) will receive vials of medication.

      Primary efficacy parameter

      Multiple gestation rate following recruitment of multiple follicular development with an AI,
      as compared to CC and FSH.

      Secondary efficacy parameters

      Rate of pregnancy obtained, live birth rate, and time to pregnancy following administration
      of an aromatase inhibitor, as compared to CC and FSH as well as the live birth rate of
      multiple gestation pregnancies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.</measure>
    <time_frame>Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Pregnancy Obtained</measure>
    <time_frame>Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pregnancy</measure>
    <time_frame>Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Pregnancy</condition>
  <condition>Unexplained Infertility</condition>
  <arm_group>
    <arm_group_label>Aromatase Inhibitors (AI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clomiphene Citrate (CC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follicle Stimulating Hormone (FSH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole (aromatase inhibitor)</intervention_name>
    <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
    <arm_group_label>Aromatase Inhibitors (AI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate</intervention_name>
    <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
    <arm_group_label>Clomiphene Citrate (CC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follicle Stimulating Hormone (gonadotropin)</intervention_name>
    <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
    <arm_group_label>Follicle Stimulating Hormone (FSH)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women ≥18 to ≤40 years of age, with one or more years infertility history, desirous of
             conceiving, regularly ovulating (defined as 9 or more menses per year), at initiation
             of participation.

          2. Normal uterine cavity and at least one open fallopian tube confirmed by
             hysterosalpingography (HSG), sonohysterography, or laparoscopy/hysteroscopy in the
             last three years preceding enrollment into the study. An uncomplicated intrauterine
             non-IVF pregnancy and uncomplicated delivery and postpartum course resulting in live
             birth within the last three years will also serve as sufficient evidence of a patent
             tube and normal uterine cavity as long as the subject did not have, during the
             pregnancy or subsequently, risk factors for Asherman's syndrome or tubal disease or
             other disorder leading to an increased suspicion for intrauterine abnormality or tubal
             occlusion.

          3. Evidence of ovarian function/reserve as assessed by day 3 (+/-2 days) FSH ≤12 IU/L
             within one year prior to study initiation.

          4. Normal or corrected thyroid function within one year of study initiation.

          5. Normal prolactin level within one year of study initiation.

          6. In general good health, not taking any medications which could interfere with the
             study (e.g., FSH, insulin sensitizers).

          7. Ability to have inseminations following hCG administration.

          8. Male partner with total motile sperm in the ejaculate of at least 5 million sperm,
             within one year of study initiation.

        Exclusion Criteria:

          1. Currently pregnant or successful pregnancies within 12 months of initiating
             participation. Clinical intrauterine miscarriages prior to initiating participation,
             within ASRM guidelines: subjects over 35 must wait six months, while subjects under 35
             must wait 12 months. No exclusion for biochemical pregnancies.

          2. Undiagnosed abnormal uterine bleeding.

          3. Suspicious ovarian mass.

          4. Patients on oral contraceptives, depo-progestins, or hormonal implants (including
             Implanon). A two month washout period will be required prior to screening for patients
             on these agents. Longer washouts may be necessary for certain depot contraceptive
             forms or implants, especially when the implants are still in place. A one-month
             washout will be required for patients on oral cyclic progestins.

          5. Known 21-hydroxylase deficiency or other enzyme defect causing congenital adrenal
             hyperplasia.

          6. Type I or Type II diabetes mellitus, or if receiving antidiabetic medications.

          7. Known significant anemia (Hemoglobin &lt;10 g/dL).

          8. History of deep venous thrombosis, pulmonary embolus, or cerebrovascular event.

          9. Known heart disease (New York Heart Association Class II or higher).

         10. Known Liver disease (defined as AST or ALT&gt;2 times normal, or total bilirubin &gt;2.5
             mg/dL).

         11. Known Renal disease (defined as BUN &gt;30 mg/dL or serum creatinine &gt; 1.4 mg/dL).

         12. History of, or suspected cervical carcinoma, endometrial carcinoma or breast
             carcinoma.

         13. History of alcohol abuse (defined as &gt;14 drinks/week) or binge drinking of ≥ 6 drinks
             at one time).

         14. Known Cushing's disease.

         15. Known or suspected adrenal or ovarian androgen secreting tumors.

         16. Allergy or contraindication to the treatment medications: AI, gonadotropins, CC or
             hCG.

         17. Couples with previous sterilization procedures (e.g. vasectomy, tubal ligation) which
             have been reversed.

         18. Patients with untreated poorly controlled hypertension defined as a systolic blood
             pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at
             least 60 minutes apart.

         19. Subjects who have undergone a bariatric surgery procedure in the recent past (&lt; 12
             months) and are in a period of acute weight loss or have been advised against
             pregnancy by their bariatric surgeon.

         20. Known moderate or severe endometriosis

         21. Known polycystic ovarian syndrome as evidenced by anovulation or oligoovulation,
             hirsutism and/or elevated testosterone levels, and ovarian morphology on ultrasound
             examination.

         22. Donated semen.

         23. Couples in which either partner is legally married to someone else.

         24. Medical conditions that are contraindications to pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Eisenberg, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nanette Santoro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Diamond, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Legro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pennsylvania State University College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Schlaff, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado Denver Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Christman, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Coutifaris, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Brzyski, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Casson, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heping Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-7333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://c2s2.yale.edu/rmn/</url>
    <description>Reproductive Medicine Network Homepage</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>January 6, 2015</results_first_submitted>
  <results_first_submitted_qc>January 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2015</results_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Heping Zhang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Infertility</keyword>
  <keyword>Ovarian stimulation</keyword>
  <keyword>Aromatase inhibitors</keyword>
  <keyword>Follicle Stimulating Hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aromatase Inhibitors (AI)</title>
          <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Letrozole (aromatase inhibitor): A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
        </group>
        <group group_id="P2">
          <title>Clomiphene Citrate (CC)</title>
          <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Clomiphene Citrate: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
        </group>
        <group group_id="P3">
          <title>Follicle Stimulating Hormone (FSH)</title>
          <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Follicle Stimulating Hormone (gonadotropin): A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="300"/>
                <participants group_id="P3" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="251"/>
                <participants group_id="P3" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aromatase Inhibitors (AI)</title>
          <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Letrozole (aromatase inhibitor): A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
        </group>
        <group group_id="B2">
          <title>Clomiphene Citrate (CC)</title>
          <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Clomiphene Citrate: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
        </group>
        <group group_id="B3">
          <title>Follicle Stimulating Hormone (FSH)</title>
          <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Follicle Stimulating Hormone (gonadotropin): A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="299"/>
            <count group_id="B2" value="300"/>
            <count group_id="B3" value="301"/>
            <count group_id="B4" value="900"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="4.3"/>
                    <measurement group_id="B2" value="32.0" spread="4.6"/>
                    <measurement group_id="B3" value="32.2" spread="4.1"/>
                    <measurement group_id="B4" value="32.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="301"/>
                    <measurement group_id="B4" value="900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="301"/>
                    <measurement group_id="B4" value="900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.</title>
        <time_frame>Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitors (AI)</title>
            <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Letrozole (aromatase inhibitor): A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
          </group>
          <group group_id="O2">
            <title>Clomiphene Citrate (CC)</title>
            <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Clomiphene Citrate: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
          </group>
          <group group_id="O3">
            <title>Follicle Stimulating Hormone (FSH)</title>
            <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Follicle Stimulating Hormone (gonadotropin): A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.</title>
          <units>number of multiples</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Pregnancy Obtained</title>
        <time_frame>Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitors (AI)</title>
            <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Letrozole (aromatase inhibitor): A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
          </group>
          <group group_id="O2">
            <title>Clomiphene Citrate (CC)</title>
            <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Clomiphene Citrate: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
          </group>
          <group group_id="O3">
            <title>Follicle Stimulating Hormone (FSH)</title>
            <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Follicle Stimulating Hormone (gonadotropin): A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Pregnancy Obtained</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Pregnancy</title>
        <time_frame>Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitors (AI)</title>
            <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Letrozole (aromatase inhibitor): A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
          </group>
          <group group_id="O2">
            <title>Clomiphene Citrate (CC)</title>
            <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Clomiphene Citrate: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
          </group>
          <group group_id="O3">
            <title>Follicle Stimulating Hormone (FSH)</title>
            <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Follicle Stimulating Hormone (gonadotropin): A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Pregnancy</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="55.6"/>
                    <measurement group_id="O2" value="67.4" spread="49.8"/>
                    <measurement group_id="O3" value="62.3" spread="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Live Birth Rate</title>
        <time_frame>Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aromatase Inhibitors (AI)</title>
            <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Letrozole (aromatase inhibitor): A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
          </group>
          <group group_id="O2">
            <title>Clomiphene Citrate (CC)</title>
            <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Clomiphene Citrate: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
          </group>
          <group group_id="O3">
            <title>Follicle Stimulating Hormone (FSH)</title>
            <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Follicle Stimulating Hormone (gonadotropin): A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
                <count group_id="O3" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Numbers of Participants at Risk are different from the numbers provided in the Participant Flow module as not all subjects who were analyzed were administered study drug and therefore not all subjects were at risk for Adverse Events. Intent-to-treat analysis kept them in the study, but they had no AE risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aromatase Inhibitors (AI)</title>
          <description>A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
Letrozole (aromatase inhibitor): A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.</description>
        </group>
        <group group_id="E2">
          <title>Clomiphene Citrate (CC)</title>
          <description>CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
Clomiphene Citrate: CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.</description>
        </group>
        <group group_id="E3">
          <title>Follicle Stimulating Hormone (FSH)</title>
          <description>A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
Follicle Stimulating Hormone (gonadotropin): A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="298"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital anomaly</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Hyperemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Neonatal Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute viral illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy of Unknown Location</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Severe pre-eclampsia; HELLP syndrome, preterm labor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Emergency C-section due to eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="298"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Presumed Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pyosalpinx Post IUI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Ovarian Hyperstimulation Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Pain due to ovarian enlargement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to shorness of breath; pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="298"/>
                <counts group_id="E3" subjects_affected="217" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="49" subjects_affected="49" subjects_at_risk="291"/>
                <counts group_id="E2" events="92" subjects_affected="92" subjects_at_risk="298"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Bloating</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="291"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="298"/>
                <counts group_id="E3" events="81" subjects_affected="81" subjects_at_risk="297"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="291"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="298"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="291"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="298"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint/Limb pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="298"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="122" subjects_affected="122" subjects_at_risk="291"/>
                <counts group_id="E2" events="104" subjects_affected="104" subjects_at_risk="298"/>
                <counts group_id="E3" events="89" subjects_affected="89" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="291"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="298"/>
                <counts group_id="E3" events="65" subjects_affected="65" subjects_at_risk="297"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heping Zhang, PhD</name_or_title>
      <organization>Yale University</organization>
      <phone>203-785-5185</phone>
      <email>heping.zhang@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

